Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
SAGA Metals Reports Final Titanium, Vanadium and Iron Assays from MRE Drilling--Maiden Mineral Resource Estimate Imminent
